<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:ns2="http://www.sec.gov/edgar/common">
    <headerData>
        <submissionType>144</submissionType>
        <filerInfo>
            <filer>
                <filerCredentials>
                    <cik>0001873392</cik>
                    <ccc>XXXXXXXX</ccc>
                </filerCredentials>
            </filer>
            <liveTestFlag>LIVE</liveTestFlag>



        </filerInfo>
    </headerData>
    <formData>
        <issuerInfo>
            <issuerCik>0001689375</issuerCik>
            <issuerName>ENTRADA THERAPEUTICS INC</issuerName>
            <secFileNumber>001-40969</secFileNumber>
            <issuerAddress>
                <ns2:street1>One Design Center Place, Suite 17-500</ns2:street1>
                <ns2:city>Boston</ns2:city>
                <ns2:stateOrCountry>MA</ns2:stateOrCountry>
                <ns2:zipCode>02210</ns2:zipCode>
            </issuerAddress>
            <issuerContactPhone>8575209158</issuerContactPhone>
            <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>NATHAN DOWDEN</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
            <relationshipsToIssuer>
                <relationshipToIssuer>Officer</relationshipToIssuer>
            </relationshipsToIssuer>
        </issuerInfo>
        <securitiesInformation>
            <securitiesClassTitle>COMMON</securitiesClassTitle>
            <brokerOrMarketmakerDetails>
                <name>Morgan Stanley Smith Barney LLC Executive Financial Services</name>
                <address>
                    <ns2:street1>1 New York Plaza</ns2:street1>
                    <ns2:street2>38th Fl.</ns2:street2>
                    <ns2:city>New York</ns2:city>
                    <ns2:stateOrCountry>NY</ns2:stateOrCountry>
                    <ns2:zipCode>10004</ns2:zipCode>
                </address>
            </brokerOrMarketmakerDetails>
            <noOfUnitsSold>7097</noOfUnitsSold>
            <aggregateMarketValue>122423.25</aggregateMarketValue>
            <noOfUnitsOutstanding>33197018</noOfUnitsOutstanding>
            <approxSaleDate>07/10/2023</approxSaleDate>
            <securitiesExchangeName>NASDAQ</securitiesExchangeName>
        </securitiesInformation>
        <securitiesToBeSold>
            <securitiesClassTitle>Common</securitiesClassTitle>
            <acquiredDate>05/22/2021</acquiredDate>
            <natureOfAcquisitionTransaction>Previously Exercised Stock Options</natureOfAcquisitionTransaction>
            <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
            <isGiftTransaction>N</isGiftTransaction>
            <amountOfSecuritiesAcquired>7097</amountOfSecuritiesAcquired>
            <paymentDate>05/22/2021</paymentDate>
            <natureOfPayment>Cash</natureOfPayment>
        </securitiesToBeSold>
        <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
        <securitiesSoldInPast3Months>
            <sellerDetails>
                <name>10b5-1 Sales Plan for NATHAN DOWDEN</name>
                <address>
                    <ns2:street1>One Design Center Place, Suite 17-500</ns2:street1>
                    <ns2:city>Boston</ns2:city>
                    <ns2:stateOrCountry>MA</ns2:stateOrCountry>
                    <ns2:zipCode>02210</ns2:zipCode>
                </address>
            </sellerDetails>
            <securitiesClassTitle>Common</securitiesClassTitle>
            <saleDate>06/22/2023</saleDate>
            <amountOfSecuritiesSold>7097</amountOfSecuritiesSold>
            <grossProceeds>113699.49</grossProceeds>
        </securitiesSoldInPast3Months>
        <securitiesSoldInPast3Months>
            <sellerDetails>
                <name>10b5-1 Sales Plan for NATHAN DOWDEN</name>
                <address>
                    <ns2:street1>One Design Center Place, Suite 17-500</ns2:street1>
                    <ns2:city>Boston</ns2:city>
                    <ns2:stateOrCountry>MA</ns2:stateOrCountry>
                    <ns2:zipCode>02210</ns2:zipCode>
                </address>
            </sellerDetails>
            <securitiesClassTitle>Common</securitiesClassTitle>
            <saleDate>06/20/2023</saleDate>
            <amountOfSecuritiesSold>8885</amountOfSecuritiesSold>
            <grossProceeds>132703.78</grossProceeds>
        </securitiesSoldInPast3Months>
        <noticeSignature>
            <noticeDate>07/10/2023</noticeDate>
            <planAdoptionDates>
                <planAdoptionDate>03/20/2023</planAdoptionDate>
            </planAdoptionDates>
            <signature>/s/ NATHAN DOWDEN</signature>
        </noticeSignature>
    </formData>
</edgarSubmission>
[{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 4785}]
144
0001873392
XXXXXXXX
LIVE
0001689375
ENTRADA THERAPEUTICS INC
001-40969
One Design Center Place, Suite 17-500
Boston
MA
02210
8575209158
NATHAN DOWDEN
Officer
COMMON
Morgan Stanley Smith Barney LLC Executive Financial Services
1 New York Plaza
38th Fl.
New York
NY
10004
7097
122423.25
33197018
07/10/2023
NASDAQ
Common
05/22/2021
Previously Exercised Stock Options
Issuer
N
7097
05/22/2021
Cash
N
10b5-1 Sales Plan for NATHAN DOWDEN
One Design Center Place, Suite 17-500
Boston
MA
02210
Common
06/22/2023
7097
113699.49
10b5-1 Sales Plan for NATHAN DOWDEN
One Design Center Place, Suite 17-500
Boston
MA
02210
Common
06/20/2023
8885
132703.78
07/10/2023
03/20/2023
/s/ NATHAN DOWDEN